Biological Products, (No Diagnostic Substances) Industry - SEC Form 4 Insider Trading Screener
Manufacturing Sector - Chemicals - Biological Products, (No Diagnostic Substances)
100 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Share Price |
Shares Traded |
Shares Owned |
Own chg |
Value Traded |
1d ret |
1w ret |
1m ret |
6m ret |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2017-09-19 | ATRA | Atara Biotherapeutics, Inc. | Ciechanover Isaac E. | CEO | S - Sale | $15.54 | -4,400 | 1,170,745 | 0% | -$68,354 | |||||
| M | 2017-09-18 | CASI | Casi Pharmaceuticals, Inc. | He Wei-Wu | Dir | P - Purchase | $1.75 | +207,502 | 2,860,204 | +8% | +$364,149 | |||||
| D | 2017-09-19 | ONCE | Spark Therapeutics, Inc. | Faga Daniel | Chief Business Officer | S - Sale+OE | $85.00 | -1,500 | 0 | -100% | -$127,500 | |||||
2017-09-19 | MBOT | Microbot Medical Inc. | Bornstein Yoseph | Dir, 10% | S - Sale | $1.18 | -50,000 | 5,195,409 | -1% | -$59,233 | ||||||
| D | 2017-09-18 | BCRX | Biocryst Pharmaceuticals Inc | Cohen Fred E | Dir | S - Sale+OE | $5.42 | -54,250 | 119,410 | -31% | -$294,035 | |||||
| DM | 2017-09-15 | BOLD | Audentes Therapeutics, Inc. | Patterson Matthew R | Pres, CEO | S - Sale+OE | $25.06 | -10,000 | 186,814 | -5% | -$250,561 | |||||
| D | 2017-09-15 | BOLD | Audentes Therapeutics, Inc. | Nagler David | SVP, HR, Corp. Affairs | S - Sale+OE | $25.00 | -3,750 | 0 | -100% | -$93,750 | |||||
| DM | 2017-09-15 | RGNX | Regenxbio Inc. | Hayden Donald J Jr | Dir | S - Sale+OE | $28.70 | -40,000 | 0 | -100% | -$1,148,000 | |||||
2017-09-15 | RGNX | Regenxbio Inc. | Vasista Vittal | CFO | S - Sale | $27.39 | -5,000 | 97,283 | -5% | -$136,925 | ||||||
| M | 2017-09-14 | CASI | Casi Pharmaceuticals, Inc. | He Wei-Wu | Dir | P - Purchase | $1.33 | +315,327 | 2,652,702 | +13% | +$419,178 | |||||
2017-09-15 | ATRA | Atara Biotherapeutics, Inc. | Haqq Christopher | EVP, R, D, Chief Scientific Of | S - Sale | $15.30 | -6,000 | 369,305 | -2% | -$91,800 | ||||||
| D | 2017-09-14 | BLUE | Bluebird Bio, Inc. | Maraganore John | Dir | S - Sale+OE | $131.21 | -18,868 | 5,843 | -76% | -$2,475,733 | |||||
2017-09-14 | JUNO | Juno Therapeutics, Inc. | Cassidy Bernard J | GC, Secretary | S - Sale | $44.92 | -28,000 | 77,893 | -26% | -$1,257,766 | ||||||
2017-09-13 | JUNO | Juno Therapeutics, Inc. | Azelby Robert | EVP, Chief Commercial Officer | S - Sale | $44.95 | -12,850 | 37,439 | -26% | -$577,608 | ||||||
2017-09-12 | XLRN | Acceleron Pharma Inc | Rovaldi Christopher | SVP, Program Mgmt, Ops | S - Sale | $38.41 | -14,000 | 26,967 | -34% | -$537,786 | ||||||
| M | 2017-09-12 | XLRN | Acceleron Pharma Inc | Kumar Ravindra | SVP, Chief Scientific Officer | S - Sale | $38.42 | -5,113 | 90,214 | -5% | -$196,418 | |||||
| M | 2017-09-12 | XLRN | Acceleron Pharma Inc | Quisel John D | SVP, Corp. Dev., GC, Sec. | S - Sale | $38.42 | -5,113 | 57,310 | -8% | -$196,423 | |||||
2017-09-12 | XLRN | Acceleron Pharma Inc | Sherman Matthew L | EVP, Chief Medical Officer | S - Sale | $38.41 | -18,400 | 86,500 | -18% | -$706,799 | ||||||
2017-09-12 | XLRN | Acceleron Pharma Inc | McLaughlin Kevin F | SVP, CFO, Treasurer | S - Sale | $38.41 | -16,000 | 49,300 | -25% | -$614,546 | ||||||
| D | 2017-09-12 | BLUE | Bluebird Bio, Inc. | Vachon Mark | Dir | S - Sale+OE | $126.82 | -6,000 | 2,000 | -75% | -$760,923 | |||||
| D | 2017-09-12 | ONCE | Spark Therapeutics, Inc. | Faga Daniel | Chief Business Officer | S - Sale+OE | $82.50 | -6,000 | 0 | -100% | -$495,009 | |||||
2017-09-12 | MBOT | Microbot Medical Inc. | Bornstein Yoseph | Dir, 10% | S - Sale | $1.12 | -20,000 | 5,204,799 | 0% | -$22,400 | ||||||
2017-09-13 | NK | Nantkwest, Inc. | Gorlin Steve | Dir | S - Sale | $5.93 | -39,604 | 768,000 | -5% | -$234,729 | ||||||
| M | 2017-07-20 | VYGR | Voyager Therapeutics, Inc. | Ravina Bernard | Chief Medical Officer | S - Sale | $12.87 | -16,470 | 32,943 | -33% | -$211,914 | |||||
| D | 2017-09-11 | BLUE | Bluebird Bio, Inc. | Walsh Jeffrey T. | Chief Financial | S - Sale+OE | $125.73 | -4,900 | 27,305 | -15% | -$616,065 | |||||
| D | 2017-09-11 | SGEN | Seattle Genetics Inc /wa | Siegall Clay B | Pres, CEO | S - Sale+OE | $53.49 | -18,832 | 678,129 | -3% | -$1,007,257 | |||||
| D | 2017-09-08 | SGEN | Seattle Genetics Inc /wa | Himes Vaughn B | Chief Technical Officer | S - Sale+OE | $53.22 | -10,000 | 164,906 | -6% | -$532,190 | |||||
| M | 2017-09-08 | NK | Nantkwest, Inc. | Gorlin Steve | Dir | S - Sale | $6.04 | -103,841 | 807,604 | -11% | -$627,417 | |||||
2017-09-12 | CDTX | Cidara Therapeutics, Inc. | Stein Jeffrey | Pres, CEO | P - Purchase | $6.79 | +7,350 | 255,968 | +3% | +$49,907 | ||||||
| D | 2017-09-08 | TECH | Bio-Techne Corp | Lucas Roger C | Dir | S - Sale+OE | $120.94 | -100 | 1,970 | -5% | -$12,094 | |||||
| D | 2017-09-08 | RGNX | Regenxbio Inc. | Yoo Stephen | Chief Medical Officer | S - Sale+OE | $25.00 | -27,342 | 0 | -100% | -$683,550 | |||||
| D | 2017-09-07 | GILD | Gilead Sciences Inc | Washington Robin L | EVP, CFO | S - Sale+OE | $85.00 | -51,820 | 113,079 | -31% | -$4,404,700 | |||||
| D | 2017-09-07 | ONCE | Spark Therapeutics, Inc. | Faga Daniel | Chief Business Officer | S - Sale+OE | $85.02 | -3,000 | 0 | -100% | -$255,045 | |||||
| D | 2017-09-07 | BOLD | Audentes Therapeutics, Inc. | Orbimed Advisors LLC | 10% | S - Sale+OE | $22.35 | -5,000 | 4,801,638 | 0% | -$111,750 | |||||
2017-09-06 | SGEN | Seattle Genetics Inc /wa | Simpson Todd E | CFO | S - Sale | $52.00 | -9,638 | 218,377 | -4% | -$501,176 | ||||||
| D | 2017-09-06 | SGEN | Seattle Genetics Inc /wa | Cline Darren S | EVP, Commercial | S - Sale+OE | $51.94 | -5,024 | 77,230 | -6% | -$260,967 | |||||
2017-09-07 | JUNO | Juno Therapeutics, Inc. | Klausner Richard | Dir | S - Sale | $42.66 | -12,000 | 776,985 | -2% | -$511,865 | ||||||
| D | 2017-09-06 | TECH | Bio-Techne Corp | Holbrook Karen A | Dir | S - Sale+OE | $121.73 | -1,059 | 914 | -54% | -$128,909 | |||||
| M | 2017-09-06 | ATRA | Atara Biotherapeutics, Inc. | Ciechanover Isaac E. | CEO | S - Sale | $15.02 | -4,400 | 1,175,145 | 0% | -$66,066 | |||||
| D | 2017-09-06 | NBIX | Neurocrine Biosciences Inc | Lippoldt Darin | GC | S - Sale+OE | $60.00 | -100 | 13,157 | -1% | -$6,000 | |||||
| D | 2017-09-06 | NBIX | Neurocrine Biosciences Inc | Gano Kyle | Chief Business Development Off | S - Sale+OE | $60.00 | -4,607 | 73,246 | -6% | -$276,420 | |||||
| D | 2017-09-06 | NBIX | Neurocrine Biosciences Inc | Bozigian Haig P. | CHIEF DEVELOPMENT OFFICER | S - Sale+OE | $60.00 | -26,250 | 129,601 | -17% | -$1,575,000 | |||||
2017-09-06 | MBOT | Microbot Medical Inc. | Bornstein Yoseph | Dir, 10% | S - Sale | $1.01 | -45,610 | 5,224,799 | -1% | -$45,859 | ||||||
2017-08-30 | MBOT | Microbot Medical Inc. | Bornstein Yoseph | Dir, 10% | S - Sale | $1.07 | -10,000 | 5,270,409 | 0% | -$10,653 | ||||||
| M | 2017-08-24 | MBOT | Microbot Medical Inc. | Bornstein Yoseph | Dir, 10% | S - Sale | $1.06 | -25,000 | 5,280,409 | 0% | -$26,523 | |||||
| D | 2017-09-05 | NBIX | Neurocrine Biosciences Inc | Obrien Christopher Flint | CHIEF MEDICAL OFFICER | S - Sale+OE | $57.50 | -52,817 | 48,973 | -52% | -$3,036,978 | |||||
| D | 2017-09-05 | RGNX | Regenxbio Inc. | Hayden Donald J Jr | Dir | S - Sale+OE | $24.95 | -20,000 | 0 | -100% | -$499,000 | |||||
| DM | 2017-09-05 | RGNX | Regenxbio Inc. | Yoo Stephen | Chief Medical Officer | S - Sale+OE | $25.00 | -32,658 | 0 | -100% | -$816,450 | |||||
2017-09-05 | RGNX | Regenxbio Inc. | Mills Kenneth T. | Pres, CEO | S - Sale | $25.00 | -10,500 | 118,530 | -8% | -$262,500 | ||||||
| D | 2017-09-01 | GILD | Gilead Sciences Inc | Martin John C | Exec COB | S - Sale+OE | $83.11 | -73,333 | 2,996,766 | -2% | -$6,094,992 | |||||
| D | 2017-09-01 | GILD | Gilead Sciences Inc | Alton Gregg H | EVP Comm, Acs ALA, Corp, Med A | S - Sale+OE | $83.05 | -25,000 | 76,488 | -25% | -$2,076,188 | |||||
| M | 2017-09-01 | EDIT | Editas Medicine, Inc. | Bosley Katrine | Pres, CEO | S - Sale | $20.33 | -16,666 | 1,407,763 | -1% | -$338,831 | |||||
2017-09-05 | TROV | Trovagene, Inc. | Tennant Stanley | Dir | S - Sale | $0.69 | -8,334 | 209,394 | -4% | -$5,750 | ||||||
2017-09-05 | VYGR | Voyager Therapeutics, Inc. | Ravina Bernard | Chief Medical Officer | S - Sale | $10.00 | -5,490 | 17,157 | -24% | -$54,900 | ||||||
| D | 2017-09-05 | ONCE | Spark Therapeutics, Inc. | La Barge Joseph | GC | S - Sale+OE | $81.00 | -5,500 | 5,525 | -50% | -$445,500 | |||||
| D | 2017-09-01 | BLUE | Bluebird Bio, Inc. | Gregory Philip D | Chief Scientific Officer | S - Sale+OE | $126.06 | -2,250 | 29,484 | -7% | -$283,635 | |||||
| D | 2017-09-01 | BLUE | Bluebird Bio, Inc. | Davidson David | Chief Medical Officer | S - Sale+OE | $129.07 | -12,000 | 15,977 | -43% | -$1,548,904 | |||||
2017-09-01 | GNMC | Aevi Genomic Medicine, Inc. | Harper Philip R | 10% | P - Purchase | $1.20 | +83,775 | 5,179,819 | +2% | +$100,530 | ||||||
| D | 2017-08-31 | LIFE | Atyr Pharma Inc | Schimmel Paul | Dir | P - Purchase | $2.65 | +94,336 | 1,140,171 | +9% | +$249,990 | |||||
| D | 2017-08-31 | LIFE | Atyr Pharma Inc | Mendlein John | CEO, Dir | P - Purchase | $2.65 | +37,736 | 367,883 | +11% | +$100,000 | |||||
| D | 2017-08-31 | SGEN | Seattle Genetics Inc /wa | Dobmeier Eric | COO | S - Sale+OE | $52.24 | -25,000 | 117,424 | -18% | -$1,305,893 | |||||
| D | 2017-08-31 | SGEN | Seattle Genetics Inc /wa | Cline Darren S | EVP, Commercial | S - Sale+OE | $52.51 | -7,569 | 72,206 | -9% | -$397,466 | |||||
| DM | 2017-08-31 | CRSP | Crispr Therapeutics AG | Novak Rodger | CEO | S - Sale+OE | $20.76 | -18,470 | 1,148,007 | -2% | -$383,393 | |||||
2017-09-01 | EIGR | Eiger Biopharmaceuticals, Inc. | Glenn Jeffrey S | Dir | P - Purchase | $9.53 | +15,000 | 182,879 | +9% | +$142,950 | ||||||
| D | 2017-08-31 | GILD | Gilead Sciences Inc | Meyers James R | EVP Worldwide Commercial Ops | S - Sale+OE | $83.19 | -60,000 | 2,715 | -96% | -$4,991,290 | |||||
| D | 2017-09-01 | AVXS | Avexis, Inc. | Nagendran Sukumar | SVP, Chief Medical Officer | S - Sale+OE | $93.25 | -1,780 | 0 | -100% | -$165,978 | |||||
| D | 2017-08-31 | BLUE | Bluebird Bio, Inc. | Walsh Jeffrey T. | Chief Financial | S - Sale+OE | $125.01 | -12,000 | 27,305 | -31% | -$1,500,091 | |||||
| D | 2017-08-31 | BLUE | Bluebird Bio, Inc. | Schenkein David P | Dir | S - Sale+OE | $115.07 | -2,000 | 3,176 | -39% | -$230,145 | |||||
| D | 2017-08-31 | BLUE | Bluebird Bio, Inc. | Lynch Daniel | Dir | S - Sale+OE | $120.00 | -500 | 2,800 | -15% | -$60,000 | |||||
| DM | 2017-08-31 | BLUE | Bluebird Bio, Inc. | Leschly Nick | Pres, CEO | S - Sale+OE | $122.27 | -46,833 | 290,418 | -14% | -$5,726,444 | |||||
| DM | 2017-08-31 | MNTA | Momenta Pharmaceuticals Inc | Wheeler Craig A | Pres | S - Sale+OE | $17.00 | -20,367 | 553,092 | -4% | -$346,239 | |||||
| D | 2017-09-01 | SGMO | Sangamo Therapeutics, Inc | Herberts Curt A. III | Sr.VP, Chief Business Officer | S - Sale+OE | $15.00 | -15,000 | 15,833 | -49% | -$225,000 | |||||
| D | 2017-09-01 | BOLD | Audentes Therapeutics, Inc. | Prasad Suyash | SVP, Chief Med Officer | S - Sale+OE | $21.44 | -8,000 | 0 | -100% | -$171,481 | |||||
| D | 2017-08-30 | GILD | Gilead Sciences Inc | Alton Gregg H | EVP Comm, Acs ALA, Corp, Med A | S - Sale+OE | $79.00 | -50,000 | 84,238 | -37% | -$3,950,000 | |||||
| D | 2017-08-29 | ONCE | Spark Therapeutics, Inc. | High Katherine A | See Remarks | S - Sale+OE | $80.25 | -10,000 | 210,000 | -5% | -$802,541 | |||||
2017-08-31 | NVAX | Novavax Inc | Young James F | Dir | S - Sale | $1.06 | -175,000 | 0 | -100% | -$184,870 | ||||||
2017-08-29 | JUNO | Juno Therapeutics, Inc. | Azelby Robert | EVP, Chief Commercial Officer | S - Sale | $39.95 | -12,869 | 50,289 | -20% | -$514,117 | ||||||
2017-08-31 | HSKA | Heska Corp | Wisnewski Nancy | EVP, Diag. Ops, Prod. Dev. | S - Sale | $102.21 | -825 | 38,114 | -2% | -$84,327 | ||||||
| D | 2017-08-30 | HSKA | Heska Corp | McMahon John | VP, CFO | S - Sale+OE | $101.17 | -2,608 | 68 | -97% | -$263,857 | |||||
2017-08-29 | ACOR | Acorda Therapeutics Inc | Scopia Capital Management LP | 10% | P - Purchase | $19.23 | +766,201 | 8,474,728 | +10% | +$14,730,449 | ||||||
2017-08-30 | BLUE | Bluebird Bio, Inc. | Leschly Nick | Pres, CEO | S - Sale | $115.18 | -25,667 | 330,887 | -7% | -$2,956,307 | ||||||
2017-08-31 | BCLI | Brainstorm Cell Therapeutics Inc. | Arbel Irit | Dir | P - Purchase | $4.26 | +2,500 | 155,833 | +2% | +$10,650 | ||||||
| D | 2017-08-29 | CELZ | Creative Medical Technology Holdings, Inc. | Warbington Timothy | CEO, Pres, 10% | S - Sale+OE | $0.20 | -5,000 | 65,122,594 | 0% | -$1,000 | |||||
| D | 2017-08-29 | CELZ | Creative Medical Technology Holdings, Inc. | Creative Medical Health Inc. | 10% | S - Sale+OE | $0.20 | -5,000 | 58,655,927 | 0% | -$1,000 | |||||
2017-08-28 | SGEN | Seattle Genetics Inc /wa | Simpson Todd E | CFO | S - Sale | $47.89 | -4,937 | 228,015 | -2% | -$236,455 | ||||||
2017-08-28 | SGEN | Seattle Genetics Inc /wa | Siegall Clay B | Pres, CEO | S - Sale | $47.89 | -25,506 | 678,129 | -4% | -$1,221,597 | ||||||
2017-08-28 | SGEN | Seattle Genetics Inc /wa | Himes Vaughn B | Chief Technical Officer | S - Sale | $47.89 | -6,377 | 164,906 | -4% | -$305,423 | ||||||
2017-08-28 | SGEN | Seattle Genetics Inc /wa | Drachman Jonathan G | CMO, EVP, R, D | S - Sale | $47.89 | -8,502 | 133,702 | -6% | -$407,199 | ||||||
2017-08-28 | SGEN | Seattle Genetics Inc /wa | Dobmeier Eric | COO | S - Sale | $47.89 | -5,343 | 117,424 | -4% | -$255,900 | ||||||
2017-08-28 | SGEN | Seattle Genetics Inc /wa | Cline Darren S | EVP, Commercial | S - Sale | $47.89 | -1,788 | 76,868 | -2% | -$85,635 | ||||||
| DM | 2017-08-28 | CRSP | Crispr Therapeutics AG | Novak Rodger | CEO | S - Sale+OE | $20.25 | -75,795 | 1,162,624 | -6% | -$1,534,869 | |||||
| M | 2017-08-28 | CRSP | Crispr Therapeutics AG | Kulkarni Samarth | Chief Business Officer | S - Sale | $20.08 | -27,154 | 106,893 | -20% | -$545,162 | |||||
2017-08-28 | CRSP | Crispr Therapeutics AG | Emster Kurt Von | Dir | S - Sale | $19.79 | -88,011 | 1,951,359 | -4% | -$1,741,738 | ||||||
| D | 2017-08-28 | BLUE | Bluebird Bio, Inc. | Walsh Jeffrey T. | Chief Financial | S - Sale+OE | $107.06 | -1,250 | 27,305 | -4% | -$133,826 | |||||
2017-08-25 | CVM | Cel Sci Corp | Talor Eyal | Chief Scientific Officer | S - Sale | $1.91 | -769 | 118,543 | -1% | -$1,469 | ||||||
| M | 2017-08-24 | CRSP | Crispr Therapeutics AG | Emster Kurt Von | Dir | S - Sale | $19.42 | -22,781 | 2,039,370 | -1% | -$442,403 | |||||
| DM | 2017-08-24 | BLUE | Bluebird Bio, Inc. | Maraganore John | Dir | S - Sale+OE | $96.00 | -13,839 | 5,843 | -70% | -$1,328,533 | |||||
| D | 2017-08-24 | SGEN | Seattle Genetics Inc /wa | Drachman Jonathan G | CMO, EVP, R, D | S - Sale+OE | $47.54 | -10,000 | 142,204 | -7% | -$475,414 | |||||
2017-08-23 | BTX | Biotime Inc | Skibsted Russell | CFO | P - Purchase | $2.64 | +2,000 | 2,000 | New | +$5,285 | ||||||
| D | 2017-08-24 | BOLD | Audentes Therapeutics, Inc. | Newman Mary | SVP, Regulatory Affairs | S - Sale+OE | $20.00 | -10,000 | 0 | -100% | -$200,000 |
Real-time CSV? Options? Alerts? Contact us!
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |